- On December 15, 2025, the U.S. FDA approved Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65.
- Addyi was previously approved in 2015 for the treatment of HSDD in premenopausal women.
- Past research shows that between 40-55% of people advancing through menopause experience low sexual desire, and about 9% of postmenopausal women have HSDD.
On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication
Addyi was previously approved in 2015 for the treatment of HSDD in premenopausal women. Premenopause or “before” menopause refers to the reproductive time in a cisgender woman’s life when they have regular menstrual cycles.
Postmenopause refers to the time period after the person finishes menopause and no longer has a menstrual cycle. The majority of people start menopause between the
While people can experience HSDD at any age, it is not uncommon to experience a low libido during menopause and postmenopause. Past research shows that between 40-55% of womenadvancing through menopause experience low sexual desire, and about 9% of postmenopausal women have HSDD.
With the expanded approval to postmenopausal women under 65, Medical News Today spoke with three women’s health experts to find out more about how Addyi works, its side effects, what does this approval mean for menopausal women, and any non-medication alternatives they suggest for low libido.
No comments:
Post a Comment